Biopharma & MedTech Launch Excellence

When it comes to Launch Excellence of innovative prescription medicines, the first six months following the launch has disproportionately high influence on the later success of the product in most key markets. Over the last 20 years, the focus of Launch Excellence shifted from mass market, primary care products to specialty medicines, which nowadays represent half of all medicines spending in the developed markets. One of the reasons of this switch was the relative reduction in the high unmet need in primary care and existing un-addressed need in specialty areas. Furthermore, rare diseases have become to represent a growing minority of new launches. 

In face of such industry shift, exacerbated by constrained national healthcare budgets, Biopharma and MedTech companies need to build and execute on clear Launch Excellence strategy in each key market. The Launch readiness significantly varies from company to company and even from a product to product within the same organisation. As a result there are few innovative products that achieve an excellent launch in all key markets.

​At BGM, we assist Biopharma and MedTech companies in building the optimal Launch Excellence strategies and executing them. We have assisted European organisation of Sanofi Genzyme in building its Launch Excellence program in key EU countries for its lead product Dupixent (Asthma and Atopic Dermatitis).